Spdr S&p Biotech Etf ETF News

"Halftime Report" trader Pete Najarian spots unusual activity in the options market. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/2NGeIvi  » Subscribe to CN

The 10-year Treasury bond yield rallied for its seventh-straight session, pressuring high growth and high valuation stocks.

What's Working this week are healthcare, consumer staples, and utilities. What's Not Working this week are transports, semis, and homebuilders.

Hello! The results for March and first-quarter ETF flows are in, and for this week’s wrap, we take a look at how it all shakes out.

Biotech stocks are hard for novice investors to successfully profit from, but it's worth your time to learn the techniques now. The post Recession Fears are Creating a Golden Opportunity for Biotech S

These shares are down significantly from all-time highs, but the businesses have plenty of room for growth.

The Stock Market can still work up to new highs in the coming months.

First, I discuss why the XBI Biotech ETF is a fantastic tool to track the performance of this industry.

Currently, 66 ETFs are affected, but it will be added to even more funds soon.

Smart Beta ETF report for PBE

Biotechnology sector-related exchange traded funds are on a four-day streak and gaining momentum, breaking above their short-term trend lines. On Friday, SPDR S&P Biotech ETF (NYSEArca: XBI) rose 2.9%

Brian Reynolds, chief market strategist at Reynolds Strategy, joins 'The Exchange' to discuss his outlook on the markets.

WCLD, XBI, IGV, ITB, and IWP are part of Today's Analyst Blog.

U.S. stocks are currently on sale compelling investors to buy on the dip.

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Little in biotech is working or controlling the pandemic for that matter, but the Biden Administrations Test-to-Treat initiative, announced at the State of the Union, places Todos Medical (OTCMKTS: TOMDF) in the pole position to capitalize on any iteration of pandemic going forward. TOMDF could even leapfrog big pharma giant Pfizer (NYSE: PFE ) which indicated its 3CL protease inhibitor Paxlovid was facing production constraints and is only expected to deliver 3.25 million doses in September. CEO of TOMDF Gerald Commissiong indicated in a Benzinga interview that there is “equivalent clinical activity between our compound and Pfizer’s“ and with respect to sales “it starts with a B not an M.” The company is almost totally derisked and assured a profitable path forward in testing or with the huge upside associated with a drug approval. The current market cap is $27 million and its trading pennies to the dollar.